GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apellis Pharmaceuticals Inc (NAS:APLS) » Definitions » 14-Day RSI

APLS (Apellis Pharmaceuticals) 14-Day RSI : 55.72 (As of Dec. 15, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Apellis Pharmaceuticals 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-12-15), Apellis Pharmaceuticals's 14-Day RSI is 55.72.

The industry rank for Apellis Pharmaceuticals's 14-Day RSI or its related term are showing as below:

APLS's 14-Day RSI is ranked worse than
82.01% of 1523 companies
in the Biotechnology industry
Industry Median: 44.97 vs APLS: 55.72

Competitive Comparison of Apellis Pharmaceuticals's 14-Day RSI

For the Biotechnology subindustry, Apellis Pharmaceuticals's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apellis Pharmaceuticals's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apellis Pharmaceuticals's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Apellis Pharmaceuticals's 14-Day RSI falls into.



Apellis Pharmaceuticals  (NAS:APLS) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apellis Pharmaceuticals  (NAS:APLS) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Apellis Pharmaceuticals 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Apellis Pharmaceuticals's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Apellis Pharmaceuticals Business Description

Traded in Other Exchanges
Address
100 Fifth Avenue, Waltham, MA, USA, 02451
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Executives
James George Chopas officer: See Remarks 950 WINTER STREET, WALTHAM MA 02451
A. Sinclair Dunlop director C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Pascal Deschatelets officer: Chief Operating Officer 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Timothy Eugene Sullivan officer: Chief Financial Officer 800 BOYLSTON ST., SUITE 3310, PRUDENTIAL TOWER C/O AJU IB INVESTMENT, BOSTON MA 02199
Mark Jeffrey Delong officer: Senior Vice President 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Nur Nicholson officer: Chief Technical Officer APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Cedric Francois director, 10 percent owner, officer: Chief Executive Officer 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Adam J. Townsend officer: See Remarks C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
David O. Watson officer: General Counsel 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Karen Lewis officer: Chief People Officer APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Jeffrey Eisele officer: See Remarks APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Caroline Baumal officer: Chief Medical Officer C/O APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Lukas Scheibler officer: See Remarks C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Alec Machiels director 505 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10022
Federico Grossi officer: See Remarks C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014